https://eureka.patsnap.com/resources/blog/rd-blog/gastroretentive-floating-tablet-buoyancy-control-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Pharmaceuticals & Drug Delivery
Gastroretentive Floating Tablet Patents: Who Holds Buoyancy Control

A data-backed look at gastroretentive floating tablet buoyancy control patents: filing trends since 2015, leading assignees, technology composition across 260 records, and where claim white space remains open in 2026.

260
Published Records
23%
Top-5 Share of All Records
-33%
Filing Growth 2021→2024
CN
Leading Jurisdiction

Filing growth = 2021 (18 records) → 2024 (12); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 260 records in scope (CR5), not the ranked leaders only.

Check your own idea
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Landscape Overview

A formulation-chemistry field built on three buoyancy mechanisms

Gastroretentive floating tablets keep a dosage form in the stomach longer by controlling its density relative to gastric fluid, using one of three broad mechanisms: gas-generating systems, low-density polymer matrices, or osmotic-coated cores. Across the 260 records in scope, claim activity sits almost entirely in formulation chemistry rather than device engineering — 91.9% of records carry an A61K medicinal-preparation classification, and 40.4% tie the buoyancy mechanism to a specific therapeutic activity under A61P.

Filing activity rose through the late 2010s, peaked in 2019 at 23 records, and has since eased to 12 by 2024 — a 33% decline over the 2021-2024 span. China and India dominate receiving-office volume, consistent with generic and branded-generic manufacturers using floating-tablet formulations to extend existing drug franchises rather than filing platform patents from scratch.

Filing volume by year and by IPC subclass, 2015-2026
  1. 1AMNEAL COMPLEX PROD RES LLC21
  2. 2BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL11
  3. 3GUANGZHOU BOSITAO CONTROLLED RELEASE PHARMA CO LTD11
  4. 4SUN PHARMACEUTICAL INDUSTRIES LTD9
  5. 5UNIV DEGLI STUDI DI GENOVA8
  6. 6MICRO LABS LIMITED8
  7. 7ELLIPSE PHARMA7
  8. 8ZHUOHE PHARM GRP CO LTD6
  9. 9RANBAXY LABORATORIES LTD6
  10. 10SICHUAN JIUZHANG BIO TECH CO LTD5
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
Filing Data

Filing trends and technology composition

Filing activity across the 260 records in scope shows a field that grew steadily through the late 2010s, peaked, and has since settled into a lower but still active baseline — with formulation chemistry, not device engineering, absorbing almost all the claim volume.

A 2019 peak followed by a real but partial pullback

Filings rose from 11 in 2017 to a peak of 23 in 2019, then eased to 18 by 2021 and 12 by 2024 — a 33% decline over that three-year span. 2025 and 2026 figures are still incomplete because publication lags filing by roughly 18 months, so the most recent years understate actual activity.

A 2019 peak followed by a real but partial pullback0613192511201720182320192320202021202220232024202552026Most recent year is partial — publication lag means later filings are not yet visible.

Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.

Formulation claims dominate; device and food/agrochemical uses are thin

A61K (medicinal preparations) appears on 91.9% of the 260 records and A61P (therapeutic activity) on 40.4%, confirming this is overwhelmingly a formulation-chemistry field. Every other subclass — heterocyclic compounds, containers, food formulations, 3D printing, agrochemicals — sits at 2.3% or below, marking the thin branches around the formulation core.

Formulation claims dominate; device and food/agrochemical uses are thinA61K · Medicinal preparations23991.9%A61P · Therapeutic activity of compou…10540.4%C07D · Heterocyclic compounds62.3%A61J · Containers for medicine51.9%C07C · Acyclic & carbocyclic compounds51.9%A23L · Foods & non-alcoholic beverages41.5%B33Y · Additive manufacturing (3D pri…41.5%A01N · Biocides / agrochemicals31.2%Other4115.8%

Shares are the percentage of the 260 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape with Eureka

This page is one run against one query. Ask Eureka your own question about gastroretentive floating tablet buoyancy control patent landscape and every answer comes back with the patent numbers behind it.

Try Eureka
Representative Filing

A representative claim in the osmotic floating tablet cluster

Representative Record
US9861585B22018-01-09

US9861585B2 — Osmotic floating tablets (Sun Pharmaceutical Industries, 2018-01-09)

SUN PHARMACEUTICAL INDUSTRIES LIMITED

The present invention relates to an osmotic floating tablet comprising: (i) an inner core comprising a drug, one or more low density polymers, and one or more pharmaceutically acceptable excipients; and (ii) an outer osmotic coating surrounding the inner core that is substantially permeable to surrounding fluids and substantially impermeable to the drug. The present invention also relates to processes for the preparation of said tablets.Structural claim: low-density core plus asymmetrically permeable outer coating — a distinct architecture from gas-generating or matrix-only floating systems.

View full claim record
Most-cited records in this dataset
#Publication no.Patent titleCitations
1US4216994ATablet side arm for chairs43
2CN104887641A帕布昔利布胃漂浮片及其制备方法37
3CN103239482A一种美洲大蠊胃漂浮片及其制备方法和应用23
4US20040115259A1Method for producing a floating tablet containing an active principle and the tablet obtained23
5US20010046473A1Gastric-retained pharmaceutical composition and method for its use23
6CN101011381A一种银杏内酯类药物的胃漂浮片及其制备方法17
7WO2010143052A1Novel pharmaceutical compositions containing pregabalin16
8WO2020006278A1Self-regulating osmotic gastroretentive drug delivery systems13
9US20190175499A1Use of chlorogenic acid in preparing pharmaceuticals for treatment of LAG-3-mediated disease13
10JP2001158703AWater face-floating tablet agrochemical composition for paddy field, method for using the same and method for…13

Citation counts favour older records within the searched corpus and should be read as a signal of influence, not current relevance.

Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Signal Read

What the filing pattern actually tells you

Three figures matter more than the raw record count: how concentrated ownership is, how the trend has moved since the 2019 peak, and where claim density thins out.

Concentration
23.1% / 35.4%
top 5 / top 10 share of 260 records

No single company controls the field

The leader holds 21 records and the top 10 combined hold 92 (35.4% of all 260 records), which is real concentration but not a chokehold — most of the field is a long tail of single- or few-filing entrants.

Ranked leaders, 100 companies
Trend
18 → 12 (-33%)
2021 to 2024 filings

A real pullback from the 2019 peak, not a data gap

Filings peaked at 23 in 2019 and eased to 12 by 2024. 2024 is the last year with a complete publication record; 2025-2026 will fill in further as later-filed applications publish.

Peak year: 2019, 23 records
Composition
91.9% A61K
share of 260 records

This is a formulation field, not a device field

Medicinal-preparation claims (A61K) dominate at 91.9% of records; every non-pharmaceutical branch — 3D printing, food, agrochemical uses — sits at 1.5% or below.

IPC subclass shares, multi-label
Geography
China 86 · India 71
receiving office filings

Filing activity concentrates in generic-manufacturing markets

China and India lead receiving-office volume by a wide margin over the US (28), EPO (14) and WIPO (12), consistent with generic and branded-generic manufacturers extending existing drug franchises.

Receiving office counts
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to gastroretentive floating tablet buoyancy control patent landscape, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Derived observations on the same dataset. Derived from a Patsnap search on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Next Steps

Where to take this analysis next

The figures above set the boundaries of the field. The next questions are specific to what you are trying to file or clear.

Check a formulation against the structural claims

If you are developing a floating tablet, compare its core-and-coating or core-and-gas-chamber architecture against the structural claims held by the ranked leaders, not just against compositional excipient claims.

Run a claim comparison in Eureka

Track the post-2024 filing trend as it fills in

2025 and 2026 filings are still publishing. Revisit the trend once those years complete to see whether the 2021-2024 decline continues or levels off.

Set a filing alert in Eureka

Investigate the 3D-printing white space

B33Y-classified floating tablet filings sit at just 1.5% of records. If additive manufacturing is part of your formulation strategy, this branch warrants a closer freedom-to-operate look.

Explore white space in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Questions Practitioners Ask

Frequently asked questions

Answers are grounded in the same dataset. Derived from a Patsnap search on Gastroretentive Floating Tablet Buoyancy Control Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Gastroretentive Floating Tablet Buoyancy Control Patent Landscape in depth with Eureka

Go past this page: query the whole gastroretentive floating tablet buoyancy control patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.